AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25654354
Drug: Rifampin 20
RxNorm normalized name: rifampin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 20 mg/kg (Experimental)
Trial: 25654354
Drug: Rifampin 25
RxNorm normalized name: rifampin 25 mg/mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 25 mg/kg (Experimental)
Trial: 25654354
Drug: Rifampin 30
RxNorm normalized name: rifampin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 30 mg/kg (Experimental)
Trial: 25654354
Drug: Rifampin 35
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 35 mg/kg (Experimental)
Trial: 25654812
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) 60-mg single dose
Trial: 25655379
Drug: Siltuximab 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 5.5 mg/kg
Trial: 25655379
Drug: Siltuximab 11.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab 11.0 mg/kg
Trial: 25655379
Drug: Siltuximab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab (both doses)
Trial: 25656734
Drug: Heptavalent pneumococcal
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavalent pneumococcal conjugate vaccine (PCV7)
Trial: 25659285
Drug: Sofosbuvir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (400 mg once daily) plus Ribavirin (1000 mg or 1200 mg twice daily for 24 weeks or 12 weeks for treatment-naive genotype-2 patients)
Trial: 25660004
Drug: Transition preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition preparation program
Trial: 25664185
Drug: Atazanavir/Ritonavir 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/Ritonavir 300/100 mg qd
Trial: 25664185
Drug: Atazanavir/Ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/Ritonavir 400/100 mg qd
Trial: 25664404
Drug: Self-injection with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injection with the autoinjector (50 mg subcutaneous golimumab once monthly for 6 months)
Trial: 25664404
Drug: Self-injection with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injection with the autoinjector
Trial: 25664534
Drug: Dual mapping
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual mapping agents (radiolabeled colloid and blue dye)
Trial: 25664604
Drug: Oral octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral octreotide capsules (OOCs) 40 mg/d, escalated to 60 mg/d and then 80 mg/d for 7 months
Trial: 25665464
Drug: SB-743921 with
RxNorm normalized name: SB-743921
DrugBank: SB-743921 (DB05546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-743921 with G-CSF (9 mg/m² MTD)
Trial: 25665464
Drug: SB-743921 without
RxNorm normalized name: SB-743921
DrugBank: SB-743921 (DB05546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-743921 without G-CSF (6 mg/m² MTD)
Trial: 25667206
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 1000 mg, two doses
Trial: 25667274
Drug: Standard-of-care therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care therapies or biomarker-matched treatment groups
Trial: 25667281
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy without IGRT (from CAN-NCIC-SR2 trial)
Trial: 25668820
Drug: Stable antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable antiretroviral therapy
Trial: 25669310
Drug: Dietary cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cysteine intake (mean, 635 mg/d)
Trial: 25669662
Drug: Pilaralisib 400
RxNorm normalized name: Pilaralisib
DrugBank: Pilaralisib (DB11772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilaralisib 400 mg plus erlotinib 150 mg
Trial: 25670018
Drug: [(99m)Tc]Tilmanocept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(99m)Tc]Tilmanocept (50 µg, radiolabeled with either 0.5 mCi same day or 2.0 mCi next day)
Trial: 25672894
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide for 1 year
Trial: 25672916
Drug: Buparlisib (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 175 mg/m(2) on day 1 of a 21-day cycle with pegfilgrastim support (Group 1)
Trial: 25672916
Drug: Buparlisib (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (50, 80, and 100 mg/day) plus carboplatin AUC 5 and paclitaxel 80 mg/m(2) on days 1, 8, and 15 of a 28-day cycle without growth factor support (Group 2)
Trial: 25677668
Drug: Ziv-aflibercept (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept (1.25 mg, 0.05 mL intravitreal injection)
Trial: 25677851
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group (detectable TnT ≥0.01 ng/mL and BNP >440 pg/mL)
Trial: 25679067
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + nP + T (gemcitabine + nab-paclitaxel + TH-302)
Trial: 25679067
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + nP (gemcitabine + nab-paclitaxel)
Trial: 25679107
Drug: Early peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early peripheral perfusion-guided fluid therapy
Trial: 25679125
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment for 6 months
Trial: 25680594
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) plus cetuximab (400 mg/m² on day -7 and then 250 mg/m² on days 0 and +8)
Trial: 25680594
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) plus cetuximab
Trial: 25682597
Drug: PR104 (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR104 (dose ranged from 1.1 to 4 g/m(2))
Trial: 25682597
Drug: PR104 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR104 (3 g/m(2) or 4 g/m(2))
Trial: 25682597
Drug: PR104 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PR104 administration
Trial: 25683846
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.2 mg/kg weekly on days 1, 8, and 15 for two 28-day cycles)
Trial: 25683846
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (brentuximab vedotin followed by augICE)
Trial: 25684279
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV) administered under medical supervision
Trial: 25684479
Drug: Cancer survivors
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer survivors post cancer directed therapy (CDT)
Trial: 25685352
Drug: Common Mental
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation and again 14 days later.
Trial: 25685352
Drug: Common Mental
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common Mental Disorders Questionnaire (CMDQ) administered 12 months post-operation.
Trial: 25687566
Drug: Cervicovaginal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervicovaginal fluid (CVF) IL-6 ≥463 pg/mL
Trial: 25687566
Drug: 3-marker CVF
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-marker CVF model (IL-6 + CXCL1 + insulin-like growth factor binding protein-1)
Trial: 25687867
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m(2) (day 1) and capecitabine 1,000 mg/m(2) twice a day (days 1 to 14) in 21-day cycles
Trial: 25690834
Drug: Goal-Directed Fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-Directed Fluid Therapy (GDFT) using closed-loop fluid administration system with non-invasive cardiac output monitoring (Nexfin™)
Trial: 25692692
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day)
Trial: 25694653
Drug: LPV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r monotherapy (400/100 mg twice daily)
Trial: 25694653
Drug: LPV/r monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r monotherapy with FTC/TDF intensification as needed
Trial: 25695490
Drug: Decursin (D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decursin (D) 119 mg
Trial: 25695490
Drug: Decursinol angelate
RxNorm normalized name: Physalis angulata extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decursinol angelate (DA) 77 mg
Trial: 25696062
Drug: Mean counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mean counts per minute of daily PA
Trial: 25696062
Drug: Counts per
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Counts per minute of daily PA (sex-specific)
Trial: 25696919
Drug: Entospletinib (GS-9973)
RxNorm normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entospletinib (GS-9973) 800 mg twice daily
Trial: 25698370
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week) for 52 weeks
Trial: 25698370
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg/week) with methotrexate (6-8 mg/week)
Trial: 25698370
Drug: Self-injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injection of subcutaneous abatacept
Trial: 25699246
Drug: Novel brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel brain and vestibular rehabilitation treatment for PTSD
Trial: 25700037
Drug: Intracoronary cell
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary cell therapy
Trial: 25700774
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and pemetrexed (DL1: 1250 mg/500 mg)
Trial: 25700774
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and pemetrexed (DL0: 1250 mg/400 mg)
Trial: 25700774
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and pemetrexed (DL2: 1500 mg/500 mg)
Trial: 25701314
Drug: DTaP-HBV-IPV/Hib combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-HBV-IPV/Hib combination vaccine
Trial: 25704439
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) administered intravenously every 2 weeks until progression or unacceptable toxic effects
Trial: 26187031
Drug: Ledipasvir (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks
Trial: 25707037
Drug: Specific tweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific tweet content (setting quit date, use of nicotine patches)
Trial: 25709506
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (GnRH antagonist initiated on day 10)
Trial: 25709506
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C (GnRH antagonist initiated on day 20)
Trial: 25709506
Drug: Protocols B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocols B and C (GnRH antagonist protocols)
Trial: 25710456
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of panobinostat (30 mg) and carfilzomib (20/45 mg/m²)
Trial: 25710456
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of panobinostat and carfilzomib
Trial: 25710659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INR reversal <1.3 within 4 hours and systolic BP <160 mm Hg at 4 hours
Trial: 25710773
Drug: Sorbent Hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbent Hemodialysis (Allient system; Renal Solutions, Warrendale, PA)
Trial: 25710812
Drug: Insulin therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin therapy, n=8
Trial: 25711328
Drug: Neuropsychological tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuropsychological tests administered (QNPZ-8 score)
Trial: 25712364
Drug: Telaprevir monotherapy
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir monotherapy for 14 days followed by telaprevir-based triple therapy after 4.3 to 5.7 years
Trial: 25712496
Drug: Breath holds
RxNorm normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath holds ending on either inhalation or exhalation
Trial: 25712687
Drug: BI-505 (0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI-505 (0.09 mg/kg or higher doses)
Trial: 25712687
Drug: BI-505 (escalating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI-505 (escalating doses from 0.0004 to 20 mg/kg)
Trial: 25712687
Drug: BI-505 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI-505 (10 mg/kg doses)
Trial: 25712687
Drug: BI-505 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI-505 (various doses)
Trial: 25713585
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone gel (Crinone 8% gel) + intercourse
Trial: 25713585
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone gel (Crinone 8% gel) + abstinence
Trial: 25713600
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg (initially in RCT phase)
Trial: 25713900
Drug: Urgent video
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urgent video capsule endoscopy (VCE)
Trial: 25714828
Drug: Anticoagulants (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (vitamin K antagonists, factor Xa inhibitors, direct thrombin inhibitors)
Trial: 25715311
Drug: Triple-Combination Cream
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-Combination Cream
Trial: 25716221
Drug: Beta-blockers (bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (bisoprolol for at least 48 hours)
Trial: 25716221
Drug: Beta-blockers (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (chronic group)
Trial: 25716544
Drug: DEBIO1143 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEBIO1143 (oral administration, doses from 5 to 900 mg)
Trial: 25716544
Drug: DEBIO1143 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEBIO1143 (oral administration, doses >80 mg)
Trial: 25716544
Drug: DEBIO1143 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEBIO1143 (oral administration)
Trial: 25719453
Drug: Darunavir/ritonavir 20/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir 20/3 mg/kg twice-daily for 2 weeks, then adjusted to 25/3 mg/kg for patients <15 kg and 375/50 mg for patients 15 to <20 kg with an optimized background regimen (OBR)
Trial: 25720077
Drug: Urinary Luteinising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary Luteinising Hormone (LH)
Trial: 25722272
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of serum anti-tissue transglutaminase antibodies during febrile illness
Trial: 25726315
Drug: LES electrical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LES electrical stimulation therapy (LES-EST) at 20 Hz, 215 μs, 3-8 mAmp, delivered over 30-minute sessions, 6-12 sessions per day, starting on day 1 after implantation.
Trial: 25726315
Drug: LES electrical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LES electrical stimulation therapy (LES-EST)
Trial: 25728526
Drug: Alisertib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib (50 mg twice daily for 7 days in 21-day cycles)
Trial: 25728732
Drug: Mild CKD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild CKD (60-89 mL/min per 1.73 m²)
Trial: 25730284
Drug: Esophageal video
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esophageal video capsule endoscopy (ECE)
Trial: 25730509
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy with raltegravir and Truvada during primary HIV infection (PHI)
Trial: 25730509
Drug: Early antiretroviral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiretroviral therapy with raltegravir and Truvada during chronic HIV infection (CHI)
Trial: 25732635
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy based on ERCC1, RRM1, and TS protein expression
Trial: 25732635
Drug: Non-individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-individualized treatment
Trial: 25733005
Drug: Pevonedistat (MLN4924)
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A) at maximum tolerated dose (MTD) of 59 mg/m².
Trial: 25733005
Drug: Pevonedistat (MLN4924)
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat (MLN4924) administered via a 60-min intravenous infusion on days 1, 4, 8 and 11 (schedule B) at maximum tolerated dose (MTD) of 83 mg/m².
Trial: 25733630
Drug: Afebrile malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afebrile malaria treatment
Trial: 25733630
Drug: S. haematobium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. haematobium treatment
Trial: 25734107
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) in TB patients
Trial: 25734107
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) in non-TB patients
Trial: 25734159
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (3.75 µg HA)
Trial: 25734159
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine without AS03 adjuvant
Trial: 25734159
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (7.5 µg HA)
Trial: 25734159
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (15 µg HA)
Trial: 25734254
Drug: Metreleptin (0.06-0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metreleptin (0.06-0.24 mg/kg · d)
Trial: 25739929
Drug: (2)H-α-tocopherol from
RxNorm normalized name: Tocopherols
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (2)H-α-tocopherol from 120 g (2)H collard greens (1.2 ± 0.1 mg)
Trial: 25740829
Drug: Belimumab therapy
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab therapy for 24 weeks